EP2138162A3
Gel comprising tenofovir or tenofovir disoproxil
Abstract
The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenoforvir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.
Term
Term ended
Projected expiry passed 1 July 2025, 1.2 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both ways
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| EP1243590A2 | Cites | European Patent Office (EPO) | XI | Search report | 1 |
| TURPIN J A: "CONSIDERATIONS AND DEVELOPMENT OF TOPICAL MICROBICIDES TO INHIBIT THE SEXUAL TRANSMISSION OF HIV", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 11, no. 8, 2002, pages 1077 - 1097, XP001105064, ISSN: 1354-3784 | Non-patent | – | – | Search report | – |
| VAN ROMPAY KOEN K A ET AL: "Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.", THE JOURNAL OF INFECTIOUS DISEASES. 15 NOV 2002, vol. 186, no. 10, 15 November 2002 (2002-11-15), pages 1508 - 1513, XP002383957, ISSN: 0022-1899 | Non-patent | – | – | Search report | – |
61 members in 31 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 586839P | United States of America | – | |
| 58683904 | United States of America | P | |
| 05771562 | European Patent Office (EPO) | A |
Members61
| Document | Office | Kind | |
|---|---|---|---|
| AU2005272032A1 | Australia | A1 | |
| CA2570877A1 | Canada | A1 | |
| WO2006017044A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2006058265A1 | United States of America | A1 | |
| TW200612955A | Taiwan Province of China | A | |
| WO2006017044A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AR050424A1 | Argentina | A1 | |
| IS8584A | Iceland | A | |
| NO20070762L | Norway | L | |
| AP2007003873A0 | African Regional Intellectual Property Organization (ARIPO) | A0 | |
| EP1773296A2 | European Patent Office (EPO) | A2 | |
| KR20070041537A | Republic of Korea | A | |
| HRP20070040A2 | Croatia | A2 | |
| MX2007000122A | Mexico | A | |
| MX2007000122A | Mexico | A | |
| IL180172A0 | Israel | A0 | |
| CN1984640A | China | A | |
| EA200700311A1 | Eurasian Patent Organization (EAPO) | A1 | |
| PL382306A1 | Poland | A1 | |
| HK1103026A | Hong Kong, China | A | |
| HK1103026A1 | Hong Kong, China | A1 | |
| US2008035155A1 | United States of America | A1 | |
| JP2008505902A | Japan | A | |
| BRPI0513196A | Brazil | A | |
| ZA200700932B | South Africa | B | |
| EP1773296B1 | European Patent Office (EPO) | B1 | |
| AT447396T | Austria | T | |
| ATE447396T1 | Austria | T1 | |
| DE602005017497D1 | Germany | D1 | |
| EP2138162A2 | European Patent Office (EPO) | A2 | |
| EP2138163A2 | European Patent Office (EPO) | A2 | |
| PT1773296E | Portugal | E | |
| HRP20100038T1 | Croatia | T1 | |
| DK1773296T3 | Denmark | T3 | |
| ES2336017T3 | Spain | T3 | |
| PL1773296T3 | Poland | T3 | |
| SI1773296T1 | Slovenia | T1 | |
| CN1984640B | China | B | |
| NZ552172A | New Zealand | A | |
| IL206031A0 | Israel | A0 | |
| RS51213B | Serbia | B | |
| UA93354C2 | Ukraine | C2 | |
| EP2283812A2 | European Patent Office (EPO) | A2 | |
| US2011120475A1 | United States of America | A1 | |
| US2011132376A1 | United States of America | A1 | |
| AU2005272032B2 | Australia | B2 | |
| EP2138162A3This record | European Patent Office (EPO) | A3 | |
| EP2138163A3 | European Patent Office (EPO) | A3 | |
| EP2283812A3 | European Patent Office (EPO) | A3 | |
| IL180172A | Israel | A | |
| JP2012255021A | Japan | A | |
| JP5121451B2 | Japan | B2 | |
| KR101225707B1 | Republic of Korea | B1 | |
| EA017763B1 | Eurasian Patent Organization (EAPO) | B1 | |
| AP2666A | African Regional Intellectual Property Organization (ARIPO) | A | |
| CA2570877C | Canada | C | |
| CY1109757T1 | Cyprus | T1 | |
| EA201370001A1 | Eurasian Patent Organization (EAPO) | A1 | |
| US9060933B2 | United States of America | B2 | |
| US2015366795A1 | United States of America | A1 | |
| US9283182B2 | United States of America | B2 |
22 legal events, as 2 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Applications withdrawn, deemed to be withdrawn, or refused after publication in hong kongWithdrawnWD | WD | HK | |
| Application deemed to be withdrawnWithdrawn18D | 18D | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA | STAA | EP | |
| Intention to grant announcedINTG | INTG | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: GRANT OF PATENT IS INTENDEDSTAA | STAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Title (correction)GEL COMPRISING TENOFOVIR OR TENOFOVIR DISOPROXILRTI1 | RTI1 | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Requests to designate patent in hong kongDE | DE | HK | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 2138162
- Application
- 91730705
Titles3
- German
- Gel enthaltend Tenofovir oder Tenofovir Disoproxil
- English
- Gel comprising tenofovir or tenofovir disoproxil
- French
- Gel comprenant du ténofovir ou du ténofovir disoproxil
Classification
- CPC, 14
- A61K9/02
- A61K9/16
- A61K31/505
- A61K31/675
- A61F6/04
- A61K9/0014
- A61P15/00
- A61P31/00
- A61P31/12
- A61P31/18
- A61P43/00
- A61K9/48
- A61K9/12
- A61K9/0034
- IPC, 6
- A61K9 06
- A61K9 12
- A61K9 48
- A61K9 16
- A61K31 675
- A61P31 18
Designated states36
- Contracting states, 31
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Iceland
- Italy
- Liechtenstein
- Lithuania
- Luxembourg
- Latvia
- Monaco
- Netherlands (Kingdom of the)
and 7 moreShow fewer
- Poland
- Portugal
- Romania
- Sweden
- Slovenia
- Slovakia
- Türkiye
- Extension states, 5
- Albania
- Bosnia and Herzegovina
- Croatia
- North Macedonia
- Yugoslavia, later Serbia and Montenegro (until 2006)